{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:01:35Z","timestamp":1790197295844,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015633","name":"The University of Alabama at Birmingham Kaul Pediatric Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope on Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jbc.2024.107892","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T08:03:45Z","timestamp":1729065825000},"page":"107892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["PP2A activation overcomes leptomeningeal dissemination in group 3 medulloblastoma"],"prefix":"10.1016","volume":"300","author":[{"given":"Nazia","family":"Nazam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8213-443X","authenticated-orcid":false,"given":"Janet R.","family":"Julson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin H.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7842-0600","authenticated-orcid":false,"given":"Andee M.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3833-0657","authenticated-orcid":false,"given":"Laura V.","family":"Bownes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Don","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-7073","authenticated-orcid":false,"given":"Swatika","family":"Butey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mroczek-Musulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ohlmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2024.107892_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jbc.2024.107892_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: the current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jbc.2024.107892_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2176\/nmc.ra.2016-0016","article-title":"Molecular classification of medulloblastoma","volume":"56","author":"Kijima","year":"2016","journal-title":"Neurol. Med. Chir (Tokyo)"},{"key":"10.1016\/j.jbc.2024.107892_bib4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1470-2045(15)00581-1","article-title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis","volume":"17","author":"Thompson","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbc.2024.107892_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-019-03307-8","article-title":"Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens","volume":"145","author":"Yeo","year":"2019","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.jbc.2024.107892_bib6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3171\/2018.11.PEDS18506","article-title":"Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth","volume":"23","author":"Fults","year":"2019","journal-title":"J.\u00a0Neurosurg. Pediatr."},{"key":"10.1016\/j.jbc.2024.107892_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2008.02.001","article-title":"Multiple pathways regulated by the tumor suppressor PP2A in transformation","volume":"14","author":"Westermarck","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jbc.2024.107892_bib8","first-page":"1","article-title":"Druggable cancer phosphatases","volume":"13","author":"Julia","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2024.107892_bib9","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1038\/s41598-018-25263-5","article-title":"FTY720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts","volume":"8","author":"Garner","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2024.107892_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biocel.2017.10.002","article-title":"Tumor suppressive protein phosphatases in human cancer: emerging targets for therapeutic intervention and tumor stratification","volume":"96","author":"Meeusen","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jbc.2024.107892_bib11","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/cancers14081952","article-title":"Pre-clinical study evaluating novel protein phosphatase 2A activators as therapeutics for neuroblastoma","volume":"14","author":"Bownes","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2024.107892_bib12","doi-asserted-by":"crossref","first-page":"fcaa002","DOI":"10.1093\/braincomms\/fcaa002","article-title":"Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma","volume":"2","author":"Merisaari","year":"2020","journal-title":"Brain Commun."},{"key":"10.1016\/j.jbc.2024.107892_bib13","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/1878-0261.13488","article-title":"PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells","volume":"17","author":"Denisova","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jbc.2024.107892_bib14","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.2147\/OTT.S248116","article-title":"miR-383 down-regulates the oncogene CIP2A to influence glioma proliferation and invasion","volume":"13","author":"Zhang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.jbc.2024.107892_bib15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s12031-020-01773-8","article-title":"2,5-Dimethyl celecoxib inhibits proliferation and cell cycle and induces apoptosis in glioblastoma by suppressing CIP2A\/PP2A\/Akt signaling axis","volume":"71","author":"Gao","year":"2021","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.jbc.2024.107892_bib16","doi-asserted-by":"crossref","first-page":"58847","DOI":"10.18632\/oncotarget.19375","article-title":"Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells","volume":"8","author":"Ming Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2024.107892_bib17","article-title":"Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models","author":"Denisova","year":"2022","journal-title":"Cancer Biol."},{"key":"10.1016\/j.jbc.2024.107892_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100898","article-title":"Leptomeningeal dissemination in pediatric brain tumors","volume":"39","author":"Cocito","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.jbc.2024.107892_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1165\/rcmb.2023-0105OC","article-title":"Evaluating novel protein phosphatase 2A activators as therapeutics for emphysema","volume":"69","author":"Soto","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jbc.2024.107892_bib20","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1021\/acsptsci.3c00117","article-title":"Small-molecule activation of protein phosphatase 2A counters bleomycin-induced fibrosis in mice","volume":"6","author":"Meshach Pillai","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jbc.2024.107892_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1042\/BST20201313","article-title":"Protein phosphatase 2A (PP2A) mutations in brain function, development, and neurologic disease","volume":"49","author":"Verbinnen","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jbc.2024.107892_bib22","first-page":"19","article-title":"Physiological regulation of Akt activity and stability","volume":"2","author":"Liao","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jbc.2024.107892_bib23","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2024.107892_bib24","first-page":"214","article-title":"Activation of Akt and Erk pathways in medulloblastoma","volume":"44","author":"Wlodarski","year":"2006","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.jbc.2024.107892_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2024.107892_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12311-019-1009-y","article-title":"Differential expression of genes for ubiquitin ligases in medulloblastoma subtypes","volume":"18","author":"Vriend","year":"2019","journal-title":"Cerebellum"},{"key":"10.1016\/j.jbc.2024.107892_bib27","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1535-7163.MCT-21-0622","article-title":"Ovarian cancers with low CIP2A tumor expression constitute an APR-246-sensitive disease subtype","volume":"21","author":"Cvrljevic","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbc.2024.107892_bib28","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-20-3651","article-title":"CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis","volume":"81","author":"Laine","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2024.107892_bib29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41467-023-36693-9","article-title":"Structural mechanism for inhibition of PP2A-B56\u03b1 and oncogenicity by CIP2A","volume":"14","author":"Pavic","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2024.107892_bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/onc.2016.235","article-title":"CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence","volume":"36","author":"Garg","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2024.107892_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/neuonc\/nos005","article-title":"Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma","volume":"14","author":"Estrada-Bernal","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jbc.2024.107892_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1006\/bbrc.2001.4352","article-title":"FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells","volume":"281","author":"Sonoda","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2024.107892_bib33","doi-asserted-by":"crossref","first-page":"109985","DOI":"10.18632\/oncotarget.22452","article-title":"FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways","volume":"8","author":"Lange","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2024.107892_bib34","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1038\/onc.2009.244","article-title":"Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity","volume":"28","author":"Switzer","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2024.107892_bib35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12885-019-5742-x","article-title":"Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma","volume":"19","author":"Park","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbc.2024.107892_bib36","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-05-2187","article-title":"Phosphatidylinositol 3\u2032-kinase\/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN","volume":"12","author":"Hartmann","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2024.107892_bib37","first-page":"3141","article-title":"PI3K\/mTOR signaling pathways in medulloblastoma","volume":"32","author":"Mohan","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbc.2024.107892_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/973912","article-title":"Inhibition of PI3K signalling selectively affects medulloblastoma cancer stem cells","volume":"2015","author":"Frasson","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jbc.2024.107892_bib39","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1541-7786.MCR-18-1193","article-title":"Potent antineoplastic effects of combined PI3Kalpha-MNK inhibition in medulloblastoma","volume":"17","author":"Eckerdt","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jbc.2024.107892_bib40","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cell.2018.01.038","article-title":"A\u00a0hematogenous route for medulloblastoma leptomeningeal metastases","volume":"172","author":"Garzia","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2024.107892_bib41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.18063\/ijb.723","article-title":"Using 3D-bioprinted models to study pediatric neural crest-derived tumors","volume":"9","author":"Quinn","year":"2023","journal-title":"Int. J. Bioprint."},{"key":"10.1016\/j.jbc.2024.107892_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/3dp-2019-0027","article-title":"3D bioprinting of glioblastoma models","volume":"4","author":"Parra-Cantu","year":"2020","journal-title":"J.\u00a03D Print. Med."},{"key":"10.1016\/j.jbc.2024.107892_bib43","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.3390\/cancers14235972","article-title":"Three-dimensional cell culture systems in pediatric and adult brain tumor precision medicine","volume":"14","author":"Riedel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2024.107892_bib44","first-page":"1","article-title":"PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells","volume":"10","author":"Otto Kauko","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2024.107892_bib45","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1158\/0008-5472.CAN-16-1134","article-title":"PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells","volume":"76","author":"Amanpreet Kaur","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2024.107892_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11060-018-2950-1","article-title":"UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts","volume":"140","author":"Garner","year":"2018","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.jbc.2024.107892_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/neuonc\/nov123","article-title":"Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses","volume":"18","author":"Friedman","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jbc.2024.107892_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005072-198901000-00005","article-title":"Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts","volume":"48","author":"X M He","year":"1989","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jbc.2024.107892_bib49","first-page":"833","article-title":"Differentiation characteristics of newly established medulloblastoma cell lines (D384 med, D425 med, and D458 med) and their transplantable xenografts","volume":"64","author":"He","year":"1991","journal-title":"Lab Invest."},{"key":"10.1016\/j.jbc.2024.107892_bib50","article-title":"Method for efficient transduction of cancer stem cells","volume":"2","author":"Walker","year":"2014","journal-title":"J.\u00a0Cancer Stem Cell Res."},{"key":"10.1016\/j.jbc.2024.107892_bib51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/neuonc\/nor231","article-title":"Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma","volume":"14","author":"Studebaker","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jbc.2024.107892_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/JP9.0000000000000024","article-title":"A\u00a0note on error bars as a graphical representation of the variability of data in biomedical research: choosing between standard deviation and standard error of the mean","volume":"2","author":"Tang","year":"2019","journal-title":"J.\u00a0Pancreatol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925824023949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925824023949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T20:54:07Z","timestamp":1732827247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925824023949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0021925824023949"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2024.107892","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PP2A activation overcomes leptomeningeal dissemination in group 3 medulloblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2024.107892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"107892"}}